Between 9 - 12% of the worlds population suffers from Chronic Kidney Disease (CKD), but with no cure, how can we develop more effective therapies for this underserved population?

-What is chronic kidney disease?
CKD is a persistent loss of kidney function and structural abnormalities that are assessed using markers of kidney damage and histological analysis.
As the disease progresses, it can lead to a variety of complications. Millions of people in the United States suffer from life-threatening complications related to chronic kidney disease each year, and it has been reported that less than 1% of the population suffers from CKD, which accounts for more than 6% of annual healthcare costs.

-The pathogenesis of chronic kidney disease
Renal diseases can be divided into glomerular diseases and tubular/interstitial diseases according to the location of the lesions.
Although there is a common decline in renal function and abnormalities in the structure of the kidney, there are differences in the causes, the location of the lesions and the markers found.
Therefore, when we are asked to conduct efficacy studies, we are often asked about the location of the lesions and the renal markers observed, depending on the client's target.

To date, there is no cure for CKD and treatment is aimed at delaying the progression of the disease and reducing its severity. Therefore, it is desirable to develop a radical drug for the treatment of chronic kidney disease.

We provide a drug efficacy evaluation service for new drug development using mouse models of CKD.
We offer four mouse models for chronic kidney disease. Each model has its own characteristics and can be used for different purposes.
- Adriamycin model: glomerular assessment
- Adenine model: tubular and interstitial assessment
- UUO model: renal fibrosis
- Folic acid model: evaluation of chronic kidney disease from acute kidney injury

If you would like a more in-depth explanation of ours models, please get in touch to learn more about how we can support you!

Learn more about SMC Laboratories, Inc.